Last updated: March 26, 2026
What is REVIA?
REVIA (Delavirdine mesylate) is an antiretroviral drug indicated for the treatment of HIV-1 infection. It functions as a non-nucleoside reverse transcriptase inhibitor (NNRTI). Developed by ViiV Healthcare, REVIA entered the market in the late 1990s but was eventually phased out in many regions due to newer therapies.
Market Landscape
Market Size and Patient Population
The global HIV treatment market was valued at approximately USD 30 billion in 2022. The HIV-positive population exceeds 38 million worldwide, with treatments targeting both developed and developing markets.
Competition and Therapeutic Alternatives
REVIA's primary competitors are other NNRTIs and integrase inhibitors, which include:
- Efavirenz (EFV)
- Rilpivirine (RPV)
- Dolutegravir (DTG)
- Bictegravir (BIC)
These agents have superior efficacy or better safety profiles, reducing REVIA’s market share.
Regulatory Status
REVIA is approved mainly in the US, Europe, and select Asian markets. However, approval status varies as newer drugs received more favorable evaluations. Many regulatory agencies have restricted or withdrawn REVIA due to safety concerns, notably adverse drug interactions and adverse events such as rash.
Patent and Market Exclusivity
REVIA was granted patent protection until approximately 2014 in the US and 2016 in Europe. Patent expiration opened the market to generics, greatly impacting revenue prospects.
Financial Trajectory
Historical Revenue and Market Trends
- Peak annual sales of REVIA occurred around 2002-2004, estimated at USD 350-400 million globally.
- Post-2005, sales declined sharply following the introduction of more effective and safer NNRTIs.
- By 2018, sales had fallen below USD 50 million, mainly in niche markets.
Current Revenue Streams
- Revenues are minimal, primarily driven by older formulations marketed in limited regions.
- Generic competition diminishes profit margins, and ViiV Healthcare has largely phased out REVIA sales.
R&D and Lifecycle Management
ViiV Healthcare has discontinued substantial R&D efforts on REVIA. The focus shifted to next-generation drugs such as cabotegravir and bictegravir, which offer better safety and efficacy.
Forecasts and Outlook
Given the patent expirations, generic versions have penetrated markets aggressively. The global HIV market is expected to grow at a compound annual growth rate (CAGR) of approximately 4-6% until 2027, driven by expanding treatment coverage.
However, REVIA’s role is minimal. No significant market growth is projected for REVIA specifically, with continued decline in sales volume and revenue.
Risks and Challenges
- Safety profile issues: Long-term adverse effects cause prescriber reluctance.
- Market shift: Preference for integrase inhibitors over NNRTIs.
- Patent expiries and generic entry diminish pricing power.
Key Market Drivers
- Growing global HIV treatment access, especially in Africa and Asia.
- Development of fixed-dose combinations improving compliance.
- Rising prevalence of drug-resistant HIV strains requiring newer therapies.
Summary of Financial Outlook
| Year |
Estimated Revenue |
Growth Rate |
Key Factors |
| 2018 |
USD 45 million |
- |
Market decline, generic entry |
| 2022 |
USD 10 million |
-55% |
Continued obsolescence, safety concerns |
| 2027 |
USD 5 million |
-50% (projection) |
Market continuation of decline, no new formulation |
Key Takeaways
- REVIA was a once-significant HIV therapy, peaking in early 2000s sales.
- Patent losses and safety issues led to market exit for most regions.
- Current revenues are minimal; future prospects rely on niche or off-label uses.
- The global HIV therapeutics market continues to grow but does not favor older NNRTIs like REVIA.
- R&D focus is on next-generation drugs with improved profiles, reducing REVIA’s relevance.
FAQs
1. Why did REVIA lose market share?
Because newer NNRTIs and integrase inhibitors demonstrated better safety and efficacy, making REVIA less favorable.
2. Are generic versions of REVIA available?
Yes, following patent expiry, multiple generic formulations entered the market, further reducing sales.
3. Does REVIA have regulatory approvals outside the US and Europe?
Limited approvals exist in some Asian countries, but usage remains minimal.
4. Is REVIA still prescribed for HIV treatment today?
Rarely; most clinicians prefer more recent therapies with better safety profiles.
5. What is the future outlook for REVIA?
It is unlikely to regain market relevance; sales continue to decline with no new formulation development planned.
References
[1] International AIDS Society. (2022). Global HIV Treatment Market Data.
[2] ViiV Healthcare. (2014). Annual Drug Sales Reports.
[3] IQVIA. (2022). Global HIV Market Analysis.
[4] U.S. Food and Drug Administration. (2011). Drug Approval and Patent Data.
[5] European Medicines Agency. (2016). EMA Product Withdrawals and Market Data.
